Meitheal Pharmaceuticals has Pemetrexed for Injection, USP 750 mg and 1 g Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched two new strengths of Pemetrexed for Injection, USP 750 mg per single-dose vial and 1 g per single-dose vial.

Meitheal will offer Pemetrexed for Injection, USP in carton of 1 vial for both new strengths.

ABOUT PEMETREXED FOR INJECTION, USP

Pemetrexed for Injection, USP is indicated:

  • In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
  • In combination with cisplatin for the initial treatment of patients with locally advance or metastatic, non-squamous NSCLC
  • As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
  • As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.
  • Limitations of Use: Pemetrexed for Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.
  • Initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

For full prescribing information and safety information, please click on the following link

Learn more about Pemetrexed for Injection, USP

This Website Uses Cookies

This website uses cookies to help us give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can read more about our use of cookies in our Privacy Policy.

Accept cookies Reject cookies